Abstract: Selected novel substituted pyrimidinone and pyridone compounds are effective for prophylaxis and treatment of diseases, such as TNF-.alpha., IL-1.beta., IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
Type:
Grant
Filed:
December 4, 1997
Date of Patent:
August 1, 2000
Assignee:
Amgen Inc.
Inventors:
Ulrike D. Spohr, Michael J. Malone, Nathan B. Mantlo
Abstract: Mpl ligand analogs having one or more changed glycosylation sites as compared to a naturally occurring mpl ligand sequence of a corresponding number of amino acids are disclosed. The invention also relates to DNA sequences encoding mpl ligand analogs, recombinant plasmids and host cells for analog expression, and therapeutic compositions including such analogs.
Abstract: The present invention is directed towards a computer apparatus for expressing a three dimensional structure of a G-CSF molecule or analogs thereof.
Abstract: The present invention relates to a process for purifying polyethylene glycols (PEGs) which utilizes hydrophobic interaction chromatography (HIC) to separate the PEGs based on their size and on their end-group functionality. The purified PEGs can be used to modify biologically active molecules and improve overall production of such molecules.
Abstract: Disclosed are nucleic acids encoding novel neurotrophic factors, designated NNT-1. Also disclosed are amino acid sequences for NNT-1 polypeptides, methods for preparing NNT-1 polypeptides, and other related aspects.
Abstract: MGDF analogs having one or more changed glycosylation sites as compared to a naturally occuring MGDF sequence of a corresponding number of amino acids are disclosed. The invention also relates to DNA sequences encoding said MGDF analogs, recombinant plasmids and host cells for analog expression, and therapeutic compositions including such analogs.
Abstract: The invention is to stable compositions of erythropoietin that contain an antimicrobial preservative thereby providing a multi-dose formulation. Preservatives useful in the pharmaceutical compositions of the present invention include benzyl alcohol, parabens, phenol and mixtures thereof. Other additives, including buffers may be included in the composition.
Abstract: Compounds of formula I are described which are useful to inhibit the formation of serum cholesterol by virtue of their ability to inhibit .beta.-hydroxy-.beta.-methylglutaryl-CoA(HMG CoA), the rate-controlling substance in the synthesis of serum cholesterol.
Abstract: This disclosure relates to a class of novel compounds of the formula: ##STR1## wherein R.sup.1 is C.sub.1 -C.sub.4 alkyl, phenyl or C.sub.1 -C.sub.4 alkylphenyl;R.sup.2 is C.sub.1 -C.sub.7 alkyl, benzyl, pyridyl, phenyl, halophenyl or dihalophenyl; andA is imidazol-1-yl, 1,2,4-triazol-1-yl or substituted imidazol-1-yl wherein the substituent is one or more groups selected from class consisting of C.sub.1 -C.sub.4 alkylthio and carboxy(C.sub.2 -C.sub.4 alkenyl);and pharmaceutically acceptable acid addition salts thereof. This invention further relates to pharmaceutical compositions containing the compounds and to the use of such compounds and compositions as anti-anaerobic agents.